Atara Biotherapeutics Provides Update on Clinical Programs …
5 days ago · U.S. FDA issues clinical hold on EBVALLO™ (tabelecleucel) and ATA3219 studies linked to EBVALLO Complete Response Letter (CRL). THOUSAND OAKS, Calif.--(BUSINESS …
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives …
Dec 19, 2022 · EBV+ PTLD is a rare, acute, and potentially deadly hematologic malignancy that occurs after transplantation when a patient’s T-cell immune response is compromised by …
Atara Biotherapeutics Provides Update on Clinical ... - Business …
6 days ago · Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219 U.S. FDA issues clinical hold on EBVALLO ™ (tabelecleucel) …
Atara Biotherapeutics Provides Update on Clinical Programs
5 days ago · U.S. FDA issues clinical hold on EBVALLO™ (tabelecleucel) and ATA3219 studies linked to EBVALLO Complete Response Letter (CRL) THOUSAND OAKS, Calif.--(BUSINESS …
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO
Jan 16, 2025 · Preservation of Future EBVALLO Milestone and Royalty Income Value to Shareholders: Atara remains eligible to receive a $60 million milestone payment from Pierre …
Atara Biotherapeutics Provides Regulatory and Business Update …
Jan 16, 2025 · Atara remains focused on preserving future EBVALLO financial value for the benefit of all stockholders. Atara has entered into a non-binding term sheet with Redmile …
Atara Biotherapeutics' Ebvallo® (tabelecleucel) Receives …
Dec 19, 2022 · THOUSAND OAKS, Calif. and CASTRES, France, Dec. 19, 2022 /PRNewswire/ -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), and Pierre Fabre today announced that the …
Tab-cel - Atara Biotherapeutics
Tab-cel®, Atara's most advanced T-cell immunotherapy in development, is a potential treatment for patients with Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative …
Atara hit with cell therapy clinical hold after FDA inspection
5 days ago · Atara linked the hold to a recent FDA inspection of a third-party manufacturing facility for Ebvallo, which resulted in a U.S. rejection of the allogeneic cell therapy.
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell …
6 days ago · FDA places a clinical hold on Atara's EBVALLO and ATA3219 programs due to GMP compliance issues at a third-party facility. Atara to pause new participant enrollment; CAR-T …
- Some results have been removed